ArticlemSphere2023
Therapeutic potential of
Article in mSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Bacteriophage Lysins as Programmable Antimicrobials: Mechanisms, Engineering, and Translational Advances.Probiotics and antimicrobial proteins · 2026Review
- Activity and Biocompatibility Evaluation of Enzybiotic Compositions Formulated withInternational journal of molecular sciences · 2026Article
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- Genomic and Biological Insights of Bacteriophage ΦBc24 TargetingCurrent issues in molecular biology · 2025Article
- Bovine ocular microbiome: the next frontier in managing Pinkeye in cattle.Animal microbiome · 2025Article
- Contribution of Leukocidin ED to the Pathogenesis of Staphylococcus aureus Endophthalmitis.Investigative ophthalmology & visual science · 2025Article
- Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis.Investigative ophthalmology & visual science · 2025Article
- New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Bacteriophages and their unique components provide limitless resources for exploitation.Frontiers in microbiology · 2024Article
- Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Bacteriophage lytic enzymes (i.e., phage lysins) are a trending alternative for general antibiotics to combat growing antimicrobial resistance. Gram-positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.